Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Generating Primary Models of Human Cancer to Aid in the Development of Clinically Relevant Oncolytic Viruses.

Keller BA, Wedge MÈ, Surendran A, Ilkow CS.

Methods Mol Biol. 2020;2058:271-284. doi: 10.1007/978-1-4939-9794-7_18.

PMID:
31486045
2.

Assessing the Completeness of Reporting in Preclinical Oncolytic Virus Therapy Studies.

Fergusson DA, Wesch NL, Leung GJ, MacNeil JL, Conic I, Presseau J, Cobey KD, Diallo JS, Auer R, Kimmelman J, Kekre N, El-Sayes N, Krishnan R, Keller BA, Ilkow C, Lalu MM.

Mol Ther Oncolytics. 2019 May 21;14:179-187. doi: 10.1016/j.omto.2019.05.004. eCollection 2019 Sep 27.

3.

Enhanced susceptibility of cancer cells to oncolytic rhabdo-virotherapy by expression of Nodamura virus protein B2 as a suppressor of RNA interference.

Bastin D, Aitken AS, Pelin A, Pikor LA, Crupi MJF, Huh MS, Bourgeois-Daigneault MC, Bell JC, Ilkow CS.

J Immunother Cancer. 2018 Jun 19;6(1):62. doi: 10.1186/s40425-018-0366-2.

4.

Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy.

Achard C, Surendran A, Wedge ME, Ungerechts G, Bell J, Ilkow CS.

EBioMedicine. 2018 May;31:17-24. doi: 10.1016/j.ebiom.2018.04.020. Epub 2018 Apr 23. Review.

5.

Dimethyl fumarate potentiates oncolytic virotherapy through NF-κB inhibition.

Selman M, Ou P, Rousso C, Bergeron A, Krishnan R, Pikor L, Chen A, Keller BA, Ilkow C, Bell JC, Diallo JS.

Sci Transl Med. 2018 Jan 24;10(425). pii: eaao1613. doi: 10.1126/scitranslmed.aao1613.

PMID:
29367345
6.

A Viro-Immunotherapy Triple Play for the Treatment of Glioblastoma.

Bell JC, Ilkow CS.

Cancer Cell. 2017 Aug 14;32(2):133-134. doi: 10.1016/j.ccell.2017.07.012.

7.

Complement inhibition enables tumor delivery of LCMV glycoprotein pseudotyped viruses in the presence of antiviral antibodies.

Evgin L, Ilkow CS, Bourgeois-Daigneault MC, de Souza CT, Stubbert L, Huh MS, Jennings VA, Marguerie M, Acuna SA, Keller BA, Lefebvre C, Falls T, Le Boeuf F, Auer RA, Lambris JD, McCart JA, Stojdl DF, Bell JC.

Mol Ther Oncolytics. 2016 Nov 16;3:16027. eCollection 2016.

8.

VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection.

Arulanandam R, Batenchuk C, Angarita FA, Ottolino-Perry K, Cousineau S, Mottashed A, Burgess E, Falls TJ, De Silva N, Tsang J, Howe GA, Bourgeois-Daigneault MC, Conrad DP, Daneshmand M, Breitbach CJ, Kirn DH, Raptis L, Sad S, Atkins H, Huh MS, Diallo JS, Lichty BD, Ilkow CS, Le Boeuf F, Addison CL, McCart JA, Bell JC.

Cancer Cell. 2015 Aug 10;28(2):210-24. doi: 10.1016/j.ccell.2015.06.009. Epub 2015 Jul 23.

9.

Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity.

Ilkow CS, Marguerie M, Batenchuk C, Mayer J, Ben Neriah D, Cousineau S, Falls T, Jennings VA, Boileau M, Bellamy D, Bastin D, de Souza CT, Alkayyal A, Zhang J, Le Boeuf F, Arulanandam R, Stubbert L, Sampath P, Thorne SH, Paramanthan P, Chatterjee A, Strieter RM, Burdick M, Addison CL, Stojdl DF, Atkins HL, Auer RC, Diallo JS, Lichty BD, Bell JC.

Nat Med. 2015 May;21(5):530-6. doi: 10.1038/nm.3848. Epub 2015 Apr 20.

PMID:
25894825
10.

Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killing.

Arulanandam R, Batenchuk C, Varette O, Zakaria C, Garcia V, Forbes NE, Davis C, Krishnan R, Karmacharya R, Cox J, Sinha A, Babawy A, Waite K, Weinstein E, Falls T, Chen A, Hamill J, De Silva N, Conrad DP, Atkins H, Garson K, Ilkow C, Kærn M, Vanderhyden B, Sonenberg N, Alain T, Le Boeuf F, Bell JC, Diallo JS.

Nat Commun. 2015 Mar 30;6:6410. doi: 10.1038/ncomms7410.

PMID:
25817275
11.

Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques.

Evgin L, Acuna SA, Tanese de Souza C, Marguerie M, Lemay CG, Ilkow CS, Findlay CS, Falls T, Parato KA, Hanwell D, Goldstein A, Lopez R, Lafrance S, Breitbach CJ, Kirn D, Atkins H, Auer RC, Thurman JM, Stahl GL, Lambris JD, Bell JC, McCart JA.

Mol Ther. 2015 Jun;23(6):1066-1076. doi: 10.1038/mt.2015.49. Epub 2015 Mar 25.

12.

Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease.

Zhang J, Tai LH, Ilkow CS, Alkayyal AA, Ananth AA, de Souza CT, Wang J, Sahi S, Ly L, Lefebvre C, Falls TJ, Stephenson KB, Mahmoud AB, Makrigiannis AP, Lichty BD, Bell JC, Stojdl DF, Auer RC.

Mol Ther. 2014 Jul;22(7):1320-1332. doi: 10.1038/mt.2014.60. Epub 2014 Apr 3.

13.

Smac mimetics and innate immune stimuli synergize to promote tumor death.

Beug ST, Tang VA, LaCasse EC, Cheung HH, Beauregard CE, Brun J, Nuyens JP, Earl N, St-Jean M, Holbrook J, Dastidar H, Mahoney DJ, Ilkow C, Le Boeuf F, Bell JC, Korneluk RG.

Nat Biotechnol. 2014 Feb;32(2):182-90. doi: 10.1038/nbt.2806. Epub 2014 Jan 26.

14.

Phosphorylation and membrane association of the Rubella virus capsid protein is important for its anti-apoptotic function.

Willows S, Ilkow CS, Hobman TC.

Cell Microbiol. 2014 Aug;16(8):1201-10. doi: 10.1111/cmi.12272. Epub 2014 Feb 21.

PMID:
24456140
15.

From scourge to cure: tumour-selective viral pathogenesis as a new strategy against cancer.

Ilkow CS, Swift SL, Bell JC, Diallo JS.

PLoS Pathog. 2014 Jan;10(1):e1003836. doi: 10.1371/journal.ppat.1003836. Epub 2014 Jan 16. Review.

16.

Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans.

Breitbach CJ, Arulanandam R, De Silva N, Thorne SH, Patt R, Daneshmand M, Moon A, Ilkow C, Burke J, Hwang TH, Heo J, Cho M, Chen H, Angarita FA, Addison C, McCart JA, Bell JC, Kirn DH.

Cancer Res. 2013 Feb 15;73(4):1265-75. doi: 10.1158/0008-5472.CAN-12-2687. Epub 2013 Feb 7.

17.

The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers.

Parato KA, Breitbach CJ, Le Boeuf F, Wang J, Storbeck C, Ilkow C, Diallo JS, Falls T, Burns J, Garcia V, Kanji F, Evgin L, Hu K, Paradis F, Knowles S, Hwang TH, Vanderhyden BC, Auer R, Kirn DH, Bell JC.

Mol Ther. 2012 Apr;20(4):749-58. doi: 10.1038/mt.2011.276. Epub 2011 Dec 20.

18.

The Rubella virus capsid is an anti-apoptotic protein that attenuates the pore-forming ability of Bax.

Ilkow CS, Goping IS, Hobman TC.

PLoS Pathog. 2011 Feb;7(2):e1001291. doi: 10.1371/journal.ppat.1001291. Epub 2011 Feb 17.

19.

Rubella virus capsid protein: a small protein with big functions.

Ilkow CS, Willows SD, Hobman TC.

Future Microbiol. 2010 Apr;5(4):571-84. doi: 10.2217/fmb.10.27. Review.

PMID:
20353299
20.

The rubella virus capsid protein inhibits mitochondrial import.

Ilkow CS, Weckbecker D, Cho WJ, Meier S, Beatch MD, Goping IS, Herrmann JM, Hobman TC.

J Virol. 2010 Jan;84(1):119-30. doi: 10.1128/JVI.01348-09.

21.

Rubella virus capsid protein interacts with poly(a)-binding protein and inhibits translation.

Ilkow CS, Mancinelli V, Beatch MD, Hobman TC.

J Virol. 2008 May;82(9):4284-94. doi: 10.1128/JVI.02732-07. Epub 2008 Feb 27.

22.

Modulation of signaling pathways by RNA virus capsid proteins.

Urbanowski MD, Ilkow CS, Hobman TC.

Cell Signal. 2008 Jul;20(7):1227-36. doi: 10.1016/j.cellsig.2007.12.018. Epub 2008 Jan 4. Review.

PMID:
18258415
23.

Analyses of phosphorylation events in the rubella virus capsid protein: role in early replication events.

Law LJ, Ilkow CS, Tzeng WP, Rawluk M, Stuart DT, Frey TK, Hobman TC.

J Virol. 2006 Jul;80(14):6917-25.

Supplemental Content

Support Center